COMPARATIVE RESULTS OF RECOMBINANT NON-IMMUNOGENIC STAPHYLOKINASE AND TENECTEPLASE USE IN ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION IN REAL CLINICAL PRACTICE

Aim. To compare the efficacy and safety of thrombolytic therapy with recombinant non-immunogenic staphylokinase and tenecteplase in ST elevation myocardial infarction (STEMI) in real clinical practice.

Material and methods. 84 patients with onset of STEMI symptoms up to 12 hours ago were included into the non-experimental study with mixed design. Recombinant non-immunogenic staphylokinase and tenecteplase were used in 38 and 46 patients, respectively. The dynamics of the ST segment on the ECG, angiographic reperfusion criteria were evaluated as well as clinical outcomes – mortality, reinfarction, stroke, bleeding and allergic reactions.

Results. The ST-segment resolution by 70% after 180 min was achieved in 66% and 66% of patients in recombinant non-immunogenic staphylokinase group and in tenecteplase group, respectively (p=0.66) as well as antegrade coronary blood flow through the infarct-related artery TIMI II-III in 61% and 67% of patients, respectively (p=0.63). Mortality and the rate of reinfarction, intracranial bleeding, stroke, cardiogenic shock, left ventricle aneurism and thrombosis were similar in both groups. Large bleeding (otherwise intracranial one) and allergic reactions were not registered.

Conclusion. In real clinical practice the efficacy and safety of recombinant non-immunogenic staphylokinase and tenecteplase in STEMI are similar. 

1. Keeley E.C., Boura J.A., Grines C.L. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet. 2003; 361(9351): 13-20.

2. Windecker S., Hernández-AntolТn R.A., Stefanini G.G. et al. Management of ST-elevation myocardial infarction according to European and American guidelines. EuroIntervention. 2014;10 Suppl T: T23-31.

3. Cenko E., Ricci B., Kedev S. et al. Reperfusion Therapy for ST-Elevation Acute Myocardial Infarction in Eastern Europe: the ISACS-TC Registry. European Heart Journal - Quality of Care and Clinical Outcomes. 2016;2(1):45-51.

4. Alekyan B.G.,AbrosimovA.V. The current situation and future of the percutaneous coronary intervention for acute coronary syndrome in Russian Federation. Kompleksnye Problemy Serdechno-sosudistykh Zabolevaniy. 2013;(1):5-9. (In Russ.) [Алекян Б.Г., Абросимов А.В. Современное состояние рентгенэндоваскулярного лечения острого коронарного синдрома и перспективы его развития в Российской Федерации. Комплексные Проблемы Сердечно-сосудистых Заболеваний. 2013;(1): 5-9].

5. Kashtalap V.V., Zavyrylina I.N., Barbarash O.L. Endovascularrevascularization for ST-elevation acute coronary syndrome in Russia: problems and prospects forthe further development. Kreativnaya Kardiologiya. 2015;3:5-15 (In Russ.) [Кашталап В.В., Завырылина И.Н., Барбараш О.Л. Эндоваскулярная реваскуляризация при остром коронарном синдроме с подъемом сегмента ST в России: проблемы и перспективы дальнейшего развития. Креативная Кардиология. 2015;3:5-15].

6. Markin S.S., SemenovA.M.,Arzamascev E.V. et al. Fortelyzin in patients with acute myocardial infarction. Meditsinskiy Akademicheskiy Zhurnal. 2012;12(1):80-6. (In Russ.) [Маркин С.С., Семенов А.М., Арзамасцев Е.В. и др. Доклиническое и клиническое исследование фибринселективного тромболитического препарата Фортелизин. Медицинский Академический Журнал. 2012;12(1): 80-6].

7. Oshchepkova E.V., Kolobova I.D., Efremova Y.E. On the session of the chief cardiologist from subjects of Russian Federation June 3, 2016. Kardiologicheskij Vestnik. 2016;11(3):4-11. (In Russ.) [Ощепкова Е.В., Коносова И.Д., Ефремова Ю.Е. О заседании профильной комиссии по кардиологии. Кардиологический Вестник. 2016;11(3):4-11].

8. Mazur E.S., Rabinovich R.M., Mazur V.V. et al. The results of use of new native thrombolytic in clinical practice. Rational Pharmacotherapy in Cardiology. 2016;12(2):160-5. (In Russ.) [Мазур Е.С., Рабинович Р.М., Мазур В.В. идр. Результаты применения в реальной клинической практике нового отечественного тромболитического препарата. Рациональная Фармакотерапия в Кардиологии. 2016;12(2):160-5].

9. Armstrong P., Gershlick A., Goldstein P. et al. Fibrinolysis or Primary PCI in ST-Segment Elevation Myocardial Infarction. N Engl J Med. 2013; 368:1379-87.

10. Windecker S., Kolh P., Alfonso F. et al. ESC/EACTS Guidelines on myocardialrevascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J. 2014;35(37):2541-619.

11. Steg P., James S., Atar D., et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). Eur Heart J. 2012;33(20):2569-619.

12. Schroder R., Zeymer U., Wegscheider K., Neuhaus K.L. Comparison of the predictive value of ST segment elevation resolution at 90 and 180 min after start of streptokinase in acute myocardial infarction: a substudy of the Hirudin for Improvement of Thrombolysis (HIT)-4 study. Eur Heart J. 1999;20:1563-71.

13. Gibson C., Cannon C., Daley W., et al. TIMI Frame Count: A Quantitative Method of Assessing Coronary Artery Flow. Circulation. 1996;93(5):879-88.

14. Perez de Prado A., Fernandez-Vazquez F., Cuellas-Ramon J., Gibson C. Coronary Angiography: Beyond Coronary Anatomy. Revista Espanola de Cardiologia (English Edition). 2006;59(6):596-608.

15. Yan A.T., Yan R.T., Cantor W.J. et al. TRANSFER-AMI Investigators. Relationship between risk stratification at admission and treatment effects of early invasive management following fibrinolysis: insights from the Trial of Routine ANgioplasty and Stenting After Fibrinolysis to Enhance Reperfusion in Acute Myocardial Infarction (TRANSFER-AMI). Eur Heart J. 2011;32(16):1994-2002.

16. Sim D.S., Jeong M.H., Ahn Y. et al. Pharmacoinvasive Strategy Versus Primary Percutaneous Coronary Intervention in Patients With ST-Segment-Elevation Myocardial Infarction: A Propensity ScoreMatched Analysis. Investigators. Circ Cardiovasc Interv. 2016;9(9). pii: e003508.

17. ElGuindy A.M. STREAM and FAST-MI - Pharmacoinvasive therapy: A continued role for fibrinolysis in the primary PCI era. Glob Cardiol Sci Pract. 2014;2014(2):56-60.

18. Carrillo X., Fernandez-Nofrerias E., Rodriguez-Leor O. et al. Early ST elevation myocardial infarction in non-capable percutaneous coronary intervention centres: in situ fibrinolysis vs. percutaneous coronary intervention transfer. Eur Heart J. 2016;37(13):1034-40.

19. Falcao F.J., Alves C.M., Barbosa A.H. et al. Predictors of in-hospital mortality in patients with ST-segment elevation myocardial infarction undergoing pharmacoinvasive treatment. Clinics. 2013;68(12):1516-20.

20. Khripun A.V., Malevanny M.V., Kulikovskikh Y.V. Pharmacoinvasive reperfusion therapy in treatment of ST-segment elevation myocardial infarction. Byulleten' NTsSSKh im. A.N. Bakuleva RAMN. 2013;14(4):50-9. (InRuss.) [ХрипунА.В.,МалеванныйМ.В.,Куликовских Я.В. Фармакоинвазивная реперфузионная терапия в лечении острого инфаркта миокарда с подъемом сегмента ST. Бюллетень НЦССХ им. А.Н. Бакулева РАМН. 2013;14(4):50-9].

21. KhripunA.V.,MalevannyM.V.,KulikovskikhY.V.,KastanyanA.A. In-patient outcomes of pharmacoinvasive reperfusion strategy for ST-elevation myocardial infarction. Rossiyskiy Kardiologicheskiy Zhurnal. 2016;(3):101-6. (In Russ.) [Хрипун А.В., Малеванный М.В., Куликовских Я.В., Кастанаян А.А. Госпитальные результаты фармакоинвазивной стратегии реперфузии в лечении пациентов с острым инфарктом миокарда и подъемом сегмента ST. Российский Кардиологический Журнал. 2016;3(131):101-6].

22. Kostogryz V.B. Results of Hospital Use of Recombinant Non-Immunogenic Staphylokinase in Patients with ST-Elevated Myocardial Infarction. Rational Pharmacotherapy in Cardiology. 2017;13(1):51-4. (In Russ.) [Костогрыз В.Б. Результаты госпитального применения рекомбинантной неиммуногенной стафилокиназы у больных острым инфарктом миокарда с подъемом сегмента ST. Рациональная Фармакотерапия в Кардиологии. 2017;13(1):51-4].